THOR - Synthorx, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
19.92
+2.51 (+14.42%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close 17.41
Open 17.50
Bid 19.50 x 900
Ask 20.00 x 1300
Day's Range 17.40 - 20.50
52 Week Range 11.00 - 20.50
Volume 168,793
Avg. Volume 112,572
Market Cap 624.741M
Beta (3Y Monthly) N/A
PE Ratio (TTM) N/A
EPS (TTM) -20.21
Earnings Date N/A
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 28.67
Trade prices are not sourced from all markets
  • GlobeNewswire 2 months ago

    Synthorx Appoints Andrew Powell, J.D., to its Board of Directors

    Synthorx, Inc. (THOR), a biotechnology company using a first-of-its-kind Expanded Genetic Alphabet platform technology to discover and develop optimized biologics for cancer and autoimmune disorders, today announced the appointment of Andrew Powell, J.D., to its board of directors. In addition, current board member Pratik Shah, Ph.D., has been appointed chairman of the board.

  • GlobeNewswire 2 months ago

    Synthorx Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

    Synthorx, Inc. (THOR), a biotechnology company using a first-of-its-kind Expanded Genetic Alphabet platform technology to discover and develop optimized biologics for cancer and autoimmune disorders, today announced the closing of its previously announced initial public offering of 13,699,636 shares of common stock, which includes the exercise in full of the underwriters’ option to purchase 1,786,909 additional shares of common stock, at a public offering price of $11.00 per share. Jefferies LLC, Leerink Partners LLC and Evercore ISI acted as joint book-running managers for the offering. H.C. Wainwright & Co., LLC acted as lead manager for the offering.

  • GlobeNewswire 2 months ago

    Synthorx Announces Pricing of Initial Public Offering

    Synthorx, Inc. (THOR), a biotechnology company using a first-of-its-kind Expanded Genetic Alphabet platform technology to discover and develop optimized biologics for cancer and autoimmune disorders, today announced the pricing of its initial public offering of 11,912,727 shares of common stock at a public offering price of $11.00 per share.  Synthorx anticipates total gross proceeds of approximately $131 million, before deducting underwriting discounts and commissions and other offering expenses. All shares of common stock are being offered by Synthorx. In addition, Synthorx has granted the underwriters a 30-day option to purchase up to an additional 1,786,909 shares of common stock at the initial public offering price.

  • Stocks pare losses, Nasdaq closes in the green
    Yahoo Finance 2 months ago

    Stocks pare losses, Nasdaq closes in the green

    Stocks pared losses after enduring a rollercoaster session ignited after the arrest of a Chinese telecommunications company executive muddled prospects of a U.S.-China trade resolution.

  • Benzinga 3 months ago

    IPO Outlook For The Week: Proteins, Fashion And Finance

    For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . Mogu Inc. (MOGU) will issue 4.75 million shares between $14 and $16 Wednesday on the New York Stock Exchange. The Chinese ...